Healthcare
Live Price
Offline$153.30
-1.00% today
1Y Change
-42.14%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Veeva Systems Inc. (VEEV) is a Healthcare stock with a market cap of $28.21B and listed on NYSE. The stock last traded around $153.30 and down 42.1% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +16.3%, EPS growth of +25.9%, a dividend yield of 0.0%. What stands out right now is revenue +16.3%, EPS +25.9%, free cash flow +29.6% with operating margin 28.7% and ROIC 9.5%. Valuation already assumes a fairly strong business story at P/E 31.0 and price/sales 8.8. Stock Foundry combines VEEV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VEEV
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VEEV Max Drawdown
-50.55%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VEEV and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.9B
-14.1% YoY
FY Net Income
$427.4M
-12.4% YoY
Free Cash Flow
$750.2M
-2.2% YoY
Revenue Growth
+16.3%
EPS Growth
+25.9%
Gross Margin
75.5%
Net Margin
28.4%
Income statement
USD
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | 3.2B | 2.7B | 2.4B | 2.2B | 1.9B |
| Gross Profit | 2.4B | 2.0B | 1.7B | 1.5B | 1.3B |
| Operating Income | 916M | 691M | 429M | 459M | 505M |
| EBITDA | 916M | 731M | 462M | 488M | 533M |
| Net Income | 909M | 714M | 526M | 488M | 427M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.4B | 1.1B | 703M | 886M | 1.1B |
| Total Assets | 9.0B | 7.3B | 5.9B | 4.8B | 3.8B |
| Total Liabilities | 1.8B | 1.5B | 1.3B | 1.1B | 905M |
| Shareholder Equity | 7.2B | 5.8B | 4.6B | 3.7B | 2.9B |
| Total Debt | 96M | 76M | 56M | 61M | 55M |
| Net Debt | -1.3B | -1.0B | -648M | -825M | -1.1B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
764M
-2.1% YoY
Capital Expenditures
14M
-5.2% YoY
Free Cash Flow
750M
-2.2% YoY
Key ratios
Gross Margin
75.5%
Operating Margin
28.7%
Net Margin
28.4%
ROE
13.4%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.